Drug Trial Radar · NCT00720941
Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma
Last checked: Nov 19, 2026Latest source record: Mar 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,110
Actual
Start
Aug 14, 2008
Primary completion
May 21, 2012
Study completion Mar 24, 2021
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jul 23, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a randomized, open-label, parallel group Phase III non inferiority study to evaluate the efficacy and safety of pazopanib compared with sunitinib in subjects with advanced renal cell carcinoma (RCC) who had not received prior systemic therapy for advanced or metastatic RCC.
Conditions
- Carcinoma, Renal Cell
Interventions
PazopanibDrug
800 mg administered once daily orally continuous dosing
SunitinibDrug
50 mg sunitinib to be administered in 6-week cycles: 50mg orally daily for 4 weeks followed by 2 weeks off treatment
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival (PFS)Time frame: From randomization until the earliest date of disease progression or date of death from any cause, assessed up to approximately 39 months
Locations
227 sites in 14 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Huntsville, Alabama
Novartis Investigative Site
Tucson, Arizona
Novartis Investigative Site
Little Rock, Arkansas
Novartis Investigative Site
Beverly Hills, California
Novartis Investigative Site
Escondido, California
Novartis Investigative Site
Fresno, California
Novartis Investigative Site
Greenbrae, California
Novartis Investigative Site
Hayward, California
Novartis Investigative Site
La Jolla, California
Novartis Investigative Site
Los Angeles, California
Novartis Investigative Site
Montebello, California
Novartis Investigative Site
Oakland, California
Novartis Investigative Site
Orange, California
Novartis Investigative Site
Roseville, California
Novartis Investigative Site
Sacramento, California
Novartis Investigative Site
Sacramento, California
Novartis Investigative Site
San Bernardino, California
Novartis Investigative Site
San Francisco, California
Novartis Investigative Site
San Jose, California
Novartis Investigative Site
Santa Clara, California
Novartis Investigative Site
South San Francisco, California
Novartis Investigative Site
Vallejo, California
Novartis Investigative Site
Walnut Creek, California
Novartis Investigative Site
Denver, Colorado
Novartis Investigative Site
Southington, Connecticut
Novartis Investigative Site
Trumbull, Connecticut
Novartis Investigative Site
Washington D.C., District of Columbia
Novartis Investigative Site
Fort Myers, Florida
Novartis Investigative Site
Miami, Florida
Novartis Investigative Site
Orlando, Florida
Novartis Investigative Site
Atlanta, Georgia
Novartis Investigative Site
Chicago, Illinois
Novartis Investigative Site
Elk Grove Village, Illinois
Novartis Investigative Site
Maywood, Illinois
Novartis Investigative Site
Peoria, Illinois
Novartis Investigative Site
Carmel, Indiana
Novartis Investigative Site
Indianapolis, Indiana
Novartis Investigative Site
Indianapolis, Indiana
Novartis Investigative Site
Cedar Rapids, Iowa
Novartis Investigative Site
Louisville, Kentucky
Showing 40 of 227 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.